View Financial HealthDuoGenic StemCells 配当と自社株買い配当金 基準チェック /06DuoGenic StemCells配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 02DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city TaiwanBoard Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$296.4m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$10m (NT$296.4m market cap, or US$9.90m).New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (NT$311.6m market cap, or US$10.7m).New Risk • Jun 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$294.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (NT$294.8m market cap, or US$9.98m).お知らせ • Feb 27DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city TaiwanNew Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$702.7m market cap, or US$21.5m).New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk Market cap is less than US$100m (NT$956.3m market cap, or US$29.2m).お知らせ • Jan 26DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024.決済の安定と成長配当データの取得安定した配当: 7607の 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: 7607の配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場DuoGenic StemCells 配当利回り対市場7607 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (7607)n/a市場下位25% (TW)1.4%市場トップ25% (TW)5.0%業界平均 (Life Sciences)1.4%アナリスト予想 (7607) (最長3年)n/a注目すべき配当: 7607は最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: 7607は最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: 7607の 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: 7607が配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YTW 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 03:18終値2026/05/22 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋DuoGenic StemCells corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 02DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026DuoGenic StemCells corporation, Annual General Meeting, Jun 25, 2026, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city Taiwan
Board Change • Feb 25No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. was the last director to join the board, commencing their role in . The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Aug 01New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$296.4m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$10m (NT$296.4m market cap, or US$9.90m).
New Risk • Jul 10New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (NT$311.6m market cap, or US$10.7m).
New Risk • Jun 24New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: NT$294.8m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Market cap is less than US$10m (NT$294.8m market cap, or US$9.98m).
お知らせ • Feb 27DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025DuoGenic StemCells corporation, Annual General Meeting, Jun 27, 2025, at 10:00 Taipei Standard Time. Location: b1 floor no,145, hsing ta rd., south district, taichung city Taiwan
New Risk • Dec 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$702.7m market cap, or US$21.5m).
New Risk • Aug 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risk Market cap is less than US$100m (NT$956.3m market cap, or US$29.2m).
お知らせ • Jan 26DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024DuoGenic StemCells corporation, Annual General Meeting, Apr 17, 2024.